- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Perioperative adjunctive esketamine during cesarean delivery mitigates depressive symptoms: JAMA
Postpartum depression (PPD) is a prevalent mental health condition affecting numerous women during the perinatal and postpartum periods which poses significant risks to both maternal and infant well-being. A recent study published in the Journal of American Medical Association revealed that esketamine administration significantly decreased the postpartum depression incidence and improved depressive symptoms during the initial postpartum period.
The study was conducted at Fujian Provincial Hospital from January 2022 to January 2023 and involved a total of 298 women. The participants of this study were aged 18 to 40 years who were undergoing elective cesarean deliveries. This single-center, double-blind, placebo-controlled, randomized clinical trial investigated the effectiveness of esketamine with emerging antidepressant properties in controlling PPD symptoms.
The participants were randomly assigned to receive either esketamine or a placebo following cesarean delivery. The esketamine group received a single intravenous injection of 0.25 mg/kg of esketamine immediately after delivery, this was followed by additional doses as an adjuvant in patient-controlled intravenous analgesia for 48 hours post-surgery, while the control group received saline.
The primary outcomes were assessed using the Edinburgh Postnatal Depression Scale (EPDS) at postpartum day 7 with positive screening for PPD defined as a score of 10 or more points on the EPDS. The results indicated a significant reduction in depression symptoms among patients who were administered esketamine when compared to the control group at postpartum day 7.
While the esketamine group expressed lower depression symptom scores and reduced pain levels, these benefits did not extend uniformly across all the postpartum assessments. There were no significant differences in PPD screening results or changes in EPDS scores between the groups at later follow-up points. The outcomes of this study emphasized the potential of esketamine as a perioperative intervention for preventing early postpartum depression.
Reference:
Chen, Y., Guo, Y., Wu, H., Tang, Y.-J., Sooranna, S. R., Zhang, L., Chen, T., Xie, X.-Y., Qiu, L.-C., & Wu, X.-D. (2024). Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery. In JAMA Network Open (Vol. 7, Issue 3, p. e240953). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2024.0953
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751